Comparative Efficacy and Safety of Vancomycin, Linezolid, Tedizolid, and Daptomycin in Treating Patients with

Jingjuan Feng1,2, Feng Xiang2,3, Jian Cheng2,3

  • 1School of Clinical Medical Sciences, Southwest Medical University, Luzhou, 646000, Sichuan, China.

Abstract

Insights

Linezolid appears to be a preferred antibiotic for treating methicillin-resistant Staphylococcus aureus (MRSA) skin infections, showing better clinical and microbiological success than vancomycin without safety differences. This finding aids in selecting effective MRSA treatments.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Clinical Medicine

Background:

  • Methicillin-resistant Staphylococcus aureus (MRSA) causes severe skin and soft tissue infections (SSTIs), leading to significant health risks and costs.
  • Current antibiotic recommendations for MRSA-SSTIs lack definitive guidance, necessitating comparative efficacy studies.

Purpose of the Study:

  • To conduct an updated network meta-analysis comparing vancomycin, linezolid, tedizolid, and daptomycin for MRSA-SSTIs.
  • To determine the preferred antibiotic agent for treating MRSA-caused SSTIs based on efficacy and safety.

Main Methods:

  • Systematic literature search of PubMed, Embase, and Cochrane Library for randomized controlled trials (RCTs).
  • Inclusion of RCTs comparing vancomycin, linezolid, tedizolid, and daptomycin for MRSA-SSTIs.
  • Statistical analysis using RevMan, ADDIS, and STATA software.

Main Results:

  • Twenty RCTs with 7804 patients were analyzed.
  • Linezolid demonstrated superior clinical (OR, 1.46; 95% CI, 1.07-1.99) and microbiological (OR, 1.89; 95% CI, 1.24-2.86) success compared to vancomycin.
  • No significant differences in safety were found between the antibiotics; linezolid ranked highest for efficacy.

Conclusions:

  • Linezolid may be a preferred antibiotic for MRSA-SSTIs due to superior clinical and microbiological outcomes.
  • The evidence suggests linezolid offers better efficacy without compromising safety compared to other agents studied.
  • Further research may solidify linezolid's role in MRSA-SSTI treatment guidelines.